Panacea Biotec bags polio vaccine supply order from UNICEF; stock surges 6%

The stock closed 3.34% higher at ₹414.40 per equity share.

This comes after the pharmaceutical player said it has received a long-term supply order from the United Nations International Children's Emergency Fund (UNICEF) for bivalent oral polio vaccines (bOPV) worth $35.65 million, or approximately ₹315 crore.

Under the contract, Panacea Biotec will supply bOPV to UNICEF between April 1, 2026, and March 31, 2030.

The total award to the company is for the supply of bOPV in 10 and 20 vial presentations, the statement said.

The supply of bOPV to UNICEF for its requirements as per the orders as may be received from time to time, it added.

Pancea Biotec stock performance

The share surged 1.72% over five days and declined by over 2% in a month. It slipped nearly 11% over six months.

On a year-to-date basis, the stock is down 5.71%.

While the scrip touched a year’s high of ₹581.90 on April 30, 2025, it reached a 52-week low of ₹271.20 per equity share on October 9, 2024.

Pancea Biotec has a total market capitalisation of ₹2,538.23 crore, as of October 3, 2025, according to data on the NSE.

Pancea Biotec Q1 results

The company reported a consolidated net profit of ₹4.05 crore in the June quarter of FY26, compared to a loss of ₹15.80 crore in the corresponding period in the previous fiscal year.

Its revenue from operations surged % year-on-year (YoY) to ₹166.70 crore during the quarter under review, as against ₹115.72 crore in the first quarter of FY25.

About the company

Panacea Biotec is an India-based pharmaceutical and biotechnology company engaged in the business of research, development, manufacture, and marketing of branded vaccines, pharmaceutical formulations, nutraceuticals, and food and nutrition products in India and international markets.